系统性硬化症中胸膜肺实质纤维弹力增生症的患病率与预后影响
该研究在来自英国和意大利两个转诊中心的359例系统性硬化症患者中评估胸膜肺实质纤维弹力增生症(PPFE)的患病率及其对生存和功能下降的影响。结果显示PPFE总患病率为18%(广泛型PPFE为11%),两个队列间无实质差异。PPFE与游离支气管异常显著相关(61% vs 25%,p<0.0001),并与更差的生存独立相关(HR 1.89,95%CI 1.10-3.25;p=0.005),不受ILD严重程度或短期肺功能变化影响。
要点
- 系统性硬化症患者中PPFE总患病率为18%,广泛型PPFE为11%。
- PPFE与游离支气管异常显著相关(61% vs 25%,p<0.0001)。
- PPFE与更差生存独立相关(HR 1.89,95%CI 1.10-3.25;p=0.005)。
核心结论
- 在系统性硬化症患者中PPFE患病率为18%,且与更差生存独立相关。
研究设计与样本
- 研究纳入来自英国和意大利两个转诊中心的359例系统性硬化症患者。
- 由两名对临床信息不知情的放射科医生独立评估首次高分辨率CT,量化ILD范围、游离支气管异常及PPFE肺叶受累百分比(四点分类量表),分歧由第三评分者裁定。
- PPFE范围分为局限型(≤2/18)和广泛型(>2/18),并评估其与功能下降和死亡率的关系。
主要发现
- PPFE总患病率为18%(广泛型PPFE为11%),两个队列间无实质差异。
- PPFE与游离支气管异常显著相关(61% vs 25%,p<0.0001)。
- PPFE与更差生存独立相关(HR 1.89,95%CI 1.10-3.25;p=0.005),不受ILD严重程度或短期肺功能变化影响。
临床怎么用
- 在系统性硬化症患者中应关注PPFE的存在,因其具有显著预后意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interstitial lung disease (ILD) in systemic sclerosis (SSc) is a major cause of morbidity and mortality, mostly presenting as non-specific interstitial pneumonia. Little is known about the prevalence of pleuroparenchymal fibroelastosis (PPFE), a specific entity affecting the visceral pleura and subpleural parenchyma. We set out to estimate PPFE prevalence in two large cohorts of SSc patients and to assess its impact on survival and functional decline.A total of 359 SSc patients, derived from two referral centres in two different countries (UK and Italy), were included. The first available high-resolution computed tomography scan was independently evaluated by two radiologists blind to clinical information, to quantify ILD extent, freestanding bronchial abnormalities, and lobar percentage involvement of PPFE on a four-point categorical scale. Discordant scores were adjudicated by a third scorer. PPFE extent was further classified as limited (≤2/18) or extensive (>2/18). Results were evaluated against functional decline and mortality.The overall prevalence of PPFE in the combined SSc population was 18% (11% with extensive PPFE), with no substantial difference between the two cohorts. PPFE was significantly linked to free-standing bronchial abnormalities (61% versus 25% in PPFE versus no PPFE; p<0.0001) and to worse survival, independently of ILD severity or short-term lung function changes (HR 1.89, 95% CI 1.10-3.25; p=0.005).In the current study, we provide an exhaustive description of PPFE prevalence and clinical impact in the largest cohort of SSc subjects published so far. PPFE presence should be carefully considered, due to its significant prognostic implications.
引用
- Bonifazi M, Sverzellati N, Negri E, et al. Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. Eur Respir J. 2020. PMID: 32299855. doi:10.1183/13993003.02135-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。